These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

203 related items for PubMed ID: 3353335

  • 1. The new antiarrhythmic drugs. How to put them to the best use.
    Anderson JL.
    Postgrad Med; 1988 Mar; 83(4):181-93. PubMed ID: 3353335
    [Abstract] [Full Text] [Related]

  • 2. [Antiarrhythmic therapy in patients with heart failure].
    Faber TS, Zehender M.
    Ther Umsch; 2000 May; 57(5):324-32. PubMed ID: 10859993
    [Abstract] [Full Text] [Related]

  • 3. Reassessment of benefit-risk ratio and treatment algorithms for antiarrhythmic drug therapy after the cardiac arrhythmia suppression trial.
    Anderson JL.
    J Clin Pharmacol; 1990 Nov; 30(11):981-9. PubMed ID: 2122984
    [Abstract] [Full Text] [Related]

  • 4. Encainide--an updated safety profile.
    Thomis JA.
    Cardiovasc Drugs Ther; 1990 Jun; 4 Suppl 3():585-94. PubMed ID: 2125837
    [Abstract] [Full Text] [Related]

  • 5. [What is the latest in anti-arrhythmia therapy?].
    Gloor HO.
    Schweiz Med Wochenschr; 1991 Nov 23; 121(47):1711-4. PubMed ID: 1720259
    [Abstract] [Full Text] [Related]

  • 6. Can antiarrhythmic drugs survive survival trials?
    Pratt CM, Waldo AL, Camm AJ.
    Am J Cardiol; 1998 Mar 19; 81(6A):24D-34D. PubMed ID: 9537220
    [Abstract] [Full Text] [Related]

  • 7. Implications of the Cardiac Arrhythmia Suppression Trial for antiarrhythmic drug treatment.
    Bigger JT.
    Am J Cardiol; 1990 Feb 20; 65(8):3D-10D; discussion 68D-71D. PubMed ID: 2106253
    [Abstract] [Full Text] [Related]

  • 8. [Proarrhythmic effects of anti-arrhythmia agents].
    Scanu P, Agostini D, Grollier G, Belin A, Valette B, Potier JC.
    Rev Med Interne; 1995 Feb 20; 16(8):602-7. PubMed ID: 7569432
    [Abstract] [Full Text] [Related]

  • 9. Early and late proarrhythmia from antiarrhythmic drug therapy.
    Morganroth J.
    Cardiovasc Drugs Ther; 1992 Feb 20; 6(1):11-4. PubMed ID: 1533532
    [Abstract] [Full Text] [Related]

  • 10. Circadian pattern of arrhythmic death in patients receiving encainide, flecainide or moricizine in the Cardiac Arrhythmia Suppression Trial (CAST).
    Peters RW, Mitchell LB, Brooks MM, Echt DS, Barker AH, Capone R, Liebson PR, Greene HL.
    J Am Coll Cardiol; 1994 Feb 20; 23(2):283-9. PubMed ID: 8294678
    [Abstract] [Full Text] [Related]

  • 11. The Cardiac Arrhythmia Suppression Trial: Implications for nursing practice.
    Kellen JC, Ettinger A, Todd L, Brezsnyak ML, Campion J, McBride R, Thomas S, Corum J, Schron E.
    Am J Crit Care; 1996 Jan 20; 5(1):19-25. PubMed ID: 8680488
    [Abstract] [Full Text] [Related]

  • 12. Antiarrhythmic agents for chronic ventricular arrhythmias.
    Nestico PF, Morganroth J.
    Compr Ther; 1987 Apr 20; 13(4):26-35. PubMed ID: 3105950
    [Abstract] [Full Text] [Related]

  • 13. The clinical use of class IC antiarrhythmic drugs.
    Abi Samra F.
    J La State Med Soc; 1989 May 20; 141(5):27-31. PubMed ID: 2499646
    [Abstract] [Full Text] [Related]

  • 14. A benefit-risk assessment of class III antiarrhythmic agents.
    Brendorp B, Pedersen O, Torp-Pedersen C, Sahebzadah N, Køber L.
    Drug Saf; 2002 May 20; 25(12):847-65. PubMed ID: 12241126
    [Abstract] [Full Text] [Related]

  • 15. Effects of encainide, flecainide, imipramine and moricizine on ventricular arrhythmias during the year after acute myocardial infarction: the CAPS.
    Cardiac Arrhythmia Pilot Study (CAPS) InvestigatorsThe CAPS Coordinating Center, University of Washington, JD-22, 1107 Northeast 45th, Room 505, Seattle, Washington 98105, USA..
    Am J Cardiol; 1988 Mar 01; 61(8):501-9. PubMed ID: 2894169
    [Abstract] [Full Text] [Related]

  • 16. Safety and utility of flecainide acetate in the routine care of patients with supraventricular tachyarrhythmias: results of a multicenter trial. The Flecainide Supraventricular Tachycardia Study Group.
    Hopson JR, Buxton AE, Rinkenberger RL, Nademanee K, Heilman JM, Kienzle MG.
    Am J Cardiol; 1996 Jan 25; 77(3):72A-82A. PubMed ID: 8607395
    [Abstract] [Full Text] [Related]

  • 17. Safety and toxicity of antiarrhythmic drug therapy: benefit versus risk.
    Podrid PJ.
    J Cardiovasc Pharmacol; 1991 Jan 25; 17 Suppl 6():S65-73. PubMed ID: 1723122
    [Abstract] [Full Text] [Related]

  • 18. Do antiarrhythmic drugs work? Some reflections on the implications of the Cardiac Arrhythmia Suppression Trial.
    Singh BN.
    Clin Cardiol; 1990 Oct 25; 13(10):725-8. PubMed ID: 2257714
    [Abstract] [Full Text] [Related]

  • 19. [Clinical evaluation of new anti-arrhythmia drugs after the CAST (Cardiac Arrhythmia Suppression Trial) study].
    Meinertz T, Zehender M, Hohnloser SH.
    Z Kardiol; 1992 Oct 25; 81 Suppl 4():145-9. PubMed ID: 1290291
    [Abstract] [Full Text] [Related]

  • 20. Antiarrhythmic therapy for ventricular arrhythmias.
    Zimmermann M.
    J Cardiovasc Pharmacol; 1991 Oct 25; 17 Suppl 6():S59-64. PubMed ID: 1723121
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.